1. Pink Sheet
  2. >>Geography
  3. >>North America
  4. >>United States

FDA Priority Review For Some Generics Urged To Address 'Market Failure'

 
• By Cathy Kelly

Senate Aging Committee hearing addresses generic drug priority reviews at FDA, compounding and publicizing a “watch list” of off-patent drugs with no competition as ways of deterring dramatic price increases for such products.

FDA should be able to establish a priority review process for generic drugs where there is minimal price competition for an off-patent drug, Gerard Anderson, professor of health policy and management at Johns Hopkins University, told the Senate Special Committee on Aging at a Dec. 9 hearing.

Such an approach would help to deter drug firms like Turing Pharmaceuticals AG and Valeant Pharmaceuticals International Inc....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

More from North America

BIO Notebook: Policy Uncertainty Constraining Dealmaking

 
• By Mandy Jackson and Joseph Haas

Highlights from Day Four of the BIO International Convention include policy concerns helping constrain dealmaking, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

Woodcock: Do Not Do The Wrong Study, Even If Against US FDA Advice

 
• By Sarah Karlin-Smith

The former CDER director said she tells sponsors not to conduct an FDA-recommended study design or randomized trial if it will not work.

AI Will Bolster, Not Squelch, Patient Voice In Clinical Research, US FDA Says

 
• By Sue Sutter

Artificial intelligence tools used for clinical research should be developed with input from patients and focus on their needs and abilities, FDA experts said.